ArticleAesthetic surgery journal. Open forum2026
Serum Sickness After Cosmetic Botulinum Toxin Type A Injections.
Article in Aesthetic surgery journal. Open forum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Botulinum toxin type A (BoNT-A) is widely used in therapeutic and cosmetic settings for neuromuscular and aesthetic indications. Although generally well tolerated, reports of hypersensitivity reactions-ranging from localized erythema to systemic immune syndromes-underscore its immunological complexity. This case report and literature review demonstrates a novel case of serum sickness following cosmetic Botox® (onabotulinumtoxin-A, Allergan Aesthetics, an AbbVie company, Irvine, CA) administration, categorizes hypersensitivity reactions according to the Gell and Coombs classification (Types I-IV), explores the role of complexing proteins and formulation excipients, and highlights emerging clinical concerns. This will underscore the need for greater vigilance in identifying systemic immune responses to BoNT-A especially within the cosmetic medicine industry.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.